drugset / Trial / NCT00051974

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NCT00051974 ↗

Phase 2 Completed 155 enrolled Millennium Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.

Timeline

Start
2002-12
Primary completion
2004-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — —